GTG Launches geneType, A Novel Comprehensive Risk Assessment Test That Covers 100% Of Women At Risk Of Developing Breast And Ovarian Cancer
Portfolio Pulse from Benzinga Newsdesk
Genetic Technologies Limited (NASDAQ: GENE) has launched geneType, a new comprehensive risk assessment test for breast and ovarian cancer, covering 100% of women at risk. The test is available to women above 30 and assesses both hereditary and sporadic cancer risks.
May 29, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genetic Technologies Limited has launched geneType, a comprehensive risk assessment test for breast and ovarian cancer, which could drive increased demand and revenue for the company.
The launch of geneType, a comprehensive risk assessment test for breast and ovarian cancer, is likely to increase demand for Genetic Technologies Limited's products, potentially boosting revenue and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100